拉喹莫德治疗亨廷顿病的安全性和有效性(LEGATO-HD):一项多中心、随机、双盲、安慰剂对照的2期研究
LEGATO-HD是一项在10个国家48个中心开展的2期研究,352例亨廷顿病患者随机接受拉喹莫德0.5 mg、1.0 mg、1.5 mg或安慰剂口服每日一次共52周。1.0 mg组与安慰剂组相比,UHDRS-TMS变化无显著差异,但尾状核体积丢失显著减少。拉喹莫德耐受性良好,无新安全性发现。
要点
- 拉喹莫德1.0 mg组UHDRS-TMS变化与安慰剂组无显著差异(最小二乘均值差0.78,95%CI -1.42至2.98,p=0.4853)。
- 拉喹莫德1.0 mg组尾状核体积变化百分比显著低于安慰剂组(最小二乘均值差-1.76%,95%CI -2.67至-0.85,p=0.0002)。
- 拉喹莫德耐受性良好,无新安全性发现;安慰剂组报告1例死亡,与治疗无关。
核心结论
- 拉喹莫德对UHDRS-TMS评估的运动症状无显著影响,但与安慰剂相比在52周时显著减少尾状核体积丢失。
- 本研究未回答更长疗程的拉喹莫德治疗是否能在临床评估中产生可检测且有意义的改变。
研究设计与样本
- LEGATO-HD为多中心、双盲、安慰剂对照的2期研究,在10个国家(加拿大、捷克共和国、德国、意大利、荷兰、葡萄牙、俄罗斯、西班牙、英国和美国)的48个中心开展。
- 纳入21-55岁、CAG重复长度36-49、有症状的亨廷顿病患者,UHDRS-TMS高于5且总功能容量评分8或更高。
- 患者按1:1:1:1随机分配至拉喹莫德0.5 mg、1.0 mg、1.5 mg或匹配安慰剂,口服每日一次,共52周。
- 因多发性硬化研究中的心血管安全性担忧,1.5 mg组在招募完成前终止。
- 主要终点为UHDRS-TMS自基线变化,次要终点为尾状核体积变化百分比,均在52周时比较1.0 mg组与安慰剂组。
主要发现
- 2014年10月28日至2018年6月19日期间,352例亨廷顿病成人(179例[51%]男性,173例[49%]女性;平均年龄43.9岁[SD 7.6],340例[97%]白人)被随机分配:拉喹莫德0.5 mg组107例,1.0 mg组107例,1.5 mg组30例,安慰剂组108例。
- 52周时UHDRS-TMS自基线最小二乘均值变化:拉喹莫德1.0 mg组为1.98(SE 0.83),安慰剂组为1.2(0.82);最小二乘均值差0.78(95%CI -1.42至2.98),p=0.4853。
- 尾状核体积最小二乘均值变化:拉喹莫德1.0 mg组为3.10%(SE 0.38),安慰剂组为4.86%(0.38);最小二乘均值差-1.76%(95%CI -2.67至-0.85),p=0.0002。
- 严重不良事件:安慰剂组8例(7%),拉喹莫德0.5 mg组7例(7%),1.0 mg组5例(5%),1.5 mg组1例(3%)。
- 安慰剂组发生1例死亡,与治疗无关。
关键数值与推荐
- 主要终点UHDRS-TMS变化的最小二乘均值差0.78(95%CI -1.42至2.98),p=0.4853,未达统计学显著。
- 次要终点尾状核体积变化百分比的最小二乘均值差-1.76%(95%CI -2.67至-0.85),p=0.0002。
- 所有拉喹莫德剂量组(0.5 mg、1.0 mg和1.5 mg)最常见的不良事件:头痛38例(16%)、腹泻24例(10%)、跌倒18例(7%)、鼻咽炎20例(8%)、流感15例(6%)、呕吐13例(5%)、关节痛11例(5%)、易激惹10例(4%)、疲劳8例(3%)、失眠8例(3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 亨廷顿病病程慢性且缓慢进展,本研究未回答更长疗程的拉喹莫德治疗是否能在临床评估中产生可检测且有意义的改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laquinimod modulates CNS inflammatory pathways thought to be involved in the pathology of Huntington's disease. Studies with laquinimod in transgenic rodent models of Huntington's disease suggested improvements in motor function, reduction of brain volume loss, and prolonged survival. We aimed to evaluate the safety and efficacy of laquinimod in improving motor function and reducing caudate volume loss in patients with Huntington's disease. METHODS: LEGATO-HD was a multicentre, double-blind, placebo-controlled, phase 2 study done at 48 sites across ten countries (Canada, Czech Republic, Germany, Italy, Netherlands, Portugal, Russia, Spain, UK, and USA). Patients aged 21-55 years with a cytosine-adenosine-guanine (CAG) repeat length of between 36 and 49 who had symptomatic Huntington's disease with a Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) of higher than 5 and a Total Functional Capacity score of 8 or higher were randomly assigned (1:1:1:1) by centralised interactive response technology to laquinimod 0·5 mg, 1·0 mg, or 1·5 mg, or to matching placebo, administered orally once daily over 52 weeks; people involved in the randomisation had no other role in the study. Participants, investigators, and study personnel were masked to treatment assignment. The 1·5 mg group was discontinued before recruitment was finished because of cardiovascular safety concerns in multiple sclerosis studies. The primary endpoint was change from baseline in the UHDRS-TMS and the secondary endpoint was percent change in caudate volume, both comparing the 1·0 mg group with the placebo group at week 52. Primary and secondary endpoints were assessed in the full analysis set (ie, all randomised patients who received at least one dose of study drug and had at least one post-baseline UHDRS-TMS assessment). Safety measures included adverse event frequency and severity, and clinical and laboratory examinations, and were assessed in the safety analysis set (ie, all randomised patients who received at least one dose of study drug). This trial is registered with ClinicalTrials.gov, NCT02215616, and EudraCT, 2014-000418-75, and is now complete. FINDINGS: Between Oct 28, 2014, and June 19, 2018, 352 adults with Huntington's disease (179 [51%] men and 173 [49%] women; mean age 43·9 [SD 7·6] years and 340 [97%] White) were randomly assigned: 107 to laquinimod 0·5 mg, 107 to laquinimod 1·0 mg, 30 to laquinimod 1·5 mg, and 108 to matching placebo. Least squares mean change from baseline in UHDRS-TMS at week 52 was 1·98 (SE 0·83) in the laquinimod 1·0 mg group and 1·2 (0·82) in the placebo group (least squares mean difference 0·78 [95% CI -1·42 to 2·98], p=0·4853). Least squares mean change in caudate volume was 3·10% (SE 0·38) in the 1·0 mg group and 4·86% (0·38) in the placebo group (least squares mean difference -1·76% [95% CI -2·67 to -0·85]; p=0·0002). Laquinimod was well tolerated and there were no new safety findings. Serious adverse events were reported by eight (7%) patients on placebo, seven (7%) on laquinimod 0·5 mg, five (5%) on laquinimod 1·0 mg, and one (3%) on laquinimod 1·5 mg. There was one death, which occurred in the placebo group and was unrelated to treatment. The most frequent adverse events in all laquinimod dosed groups (0·5 mg, 1·0 mg, and 1·5 mg) were headache (38 [16%]), diarrhoea (24 [10%]), fall (18 [7%]), nasopharyngitis (20 [8%]), influenza (15 [6%]), vomiting (13 [5%]), arthralgia (11 [5%]), irritability (ten [4%]), fatigue (eight [3%]), and insomnia (eight [3%]). INTERPRETATION: Laquinimod did not show a significant effect on motor symptoms assessed by the UHDRS-TMS, but significantly reduced caudate volume loss compared with placebo at week 52. Huntington's disease has a chronic and slowly progressive course, and this study does not address whether a longer duration of laquinimod treatment could have produced detectable and meaningful changes in the clinical assessments. FUNDING: Teva Pharmaceutical Industries.
引用
- Reilmann R, Anderson KE, Feigin A, et al. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Neurol. 2024. PMID: 38280392. doi:10.1016/S1474-4422(23)00454-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。